Neurocrine (NBIX) Q3 2026 Earnings Call Transcript
Neurocrine Biosciences reported Q3 2026 earnings with record net product sales of $1.1B, up 40% YoY. INGREZZA sales reached $801M, while CRENESSITY and VYKAT XR also showed growth. The company expects continued momentum in 2027, with key clinical milestones anticipated for osavampator and direclidine. Neurocrine raised its full-year INGREZZA sales guidance to $2.9B-$2.925B and plans to host an R&D Day in December.
How this was made
The 30-second read
Why it matters
The earnings beat and guidance lift suggest near‑term upside, while the disclosed cash position supports continued R&D investment.
Market read
Strong earnings and guidance raise expectations for Neurocrine and may boost biotech sector sentiment.
What to watch
Potential pricing headwinds and the $20M timing benefit reversal could temper upside.
Background
Neurocrine's Q3 2026 earnings call highlighted record sales across its three commercial products and raised guidance for its lead drug INGREZZA.
Ticker impact
Neurocrine reported record Q3 sales, raised full-year INGREZZA guidance to $2.9‑$2.925B and disclosed $800M cash, providing fresh earnings data.
likely upward pressure as market prices in stronger sales and guidance
Record product revenues and guidance raise expectations for 2027 growth, reducing downside risk.
Market effects
Biopharma sector may see broader optimism on specialty drug growth trends.
U.S. biotech indices could gain modestly on the earnings beat.
Limited to U.S. and international investors tracking specialty pharma pipelines.
Counterpoint
If guidance fails to materialize, the stock could face a sharp correction.
Key entities
- companyNeurocrine Biosciences
US‑listed biopharma company (NBIX) reporting Q3 results.
